You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Authors' response: ‘Focusing on HER2 as a potential therapeutic target in primary ovarian mucinous carcinomas’
  1. Benedict Yan,
  2. Gkeok Stzuan Diana Lim
  1. Department of Pathology, National University Health System and National University of Singapore, Singapore
  1. Correspondence to Dr Gkeok Stzuan Diana Lim, Department of Pathology, National University Health System and National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore; diana_gz_lim{at}nuhs.edu.sg

https://doi.org/10.1136/jclinpath-2012-200667

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In a study involving a large series of epithelial ovarian carcinomas (EOCs), McCaughan et al1 reported human epidermal growth factor receptor 2 (HER2) protein overexpression and amplification in all major histological subtypes, an observation consistent with the literature.2 ,3 Specifically, they document HER2 gene amplification in 3.0% (7/259) of serous papillary carcinomas, 2.1% (2/92) of endometrioid carcinomas, 25.0% (3/12) of mucinous carcinomas, 4.0% (1/25) of clear cell carcinomas and 11.9% (7/60) of mixed type carcinomas. Although their number of mucinous carcinomas was low (n=12), the higher prevalence of HER2 gene amplification relative to the other histological subtypes is also consistent with the literature.4 ,5

    We had previously reported similar findings of primary ovarian mucinous carcinomas having the highest prevalence of HER2 genomic …

    View Full Text

    Footnotes

    • Linked article 200616.

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles